Peraso (PRSO) 10-Q 10 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 05, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Registrant Name	MOSYS, INC.
Entity Central Index Key	0000890394
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Trading Symbol	MOSY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	CA
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		3,553,184
Entity File Number	000-32929
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0291941
Entity Address, Address Line One	2309 Bering Drive
Entity Address, City or Town	San Jose
Entity Address, Postal Zip Code	95131
City Area Code	408
Local Phone Number	418-7500
Document Quarterly Report	true
Document Transition Report	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 6,921	$ 6,053
Short-term investments		300
Accounts receivable	790	1,175
Inventories	713	968
Prepaid expenses and other	359	472
Total current assets	8,783	8,968
Property and equipment, net	86	197
Right-of-use lease asset, net	352	156
Other	17	78
Total assets	9,238	9,399
Current liabilities
Accounts payable	80	218
Deferred revenue		166
Short-term lease liability	201	166
PPP note payable, current	171
Accrued expenses and other	1,233	1,155
Total current liabilities	1,685	1,705
Convertible notes payable	3,092	2,858
PPP note payable	408
Long-term lease liability	152
Total liabilities	5,337	4,563
Commitments and contingencies (Note 4)
Stockholders’ equity
Preferred stock, $0.01 par value; 20,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 120,000 shares authorized; 3,553 shares and 2,179 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	3	2
Additional paid-in capital	245,488	243,281
Accumulated deficit	(241,590)	(238,447)
Total stockholders’ equity	3,901	4,836
Total liabilities and stockholders’ equity	$ 9,238	$ 9,399

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	3,553,000	2,179,000
Common stock, shares outstanding	3,553,000	2,179,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net revenue
Total net revenue	$ 1,971,000	$ 1,206,000	$ 5,199,000	$ 7,792,000
Cost of net revenue	677,000	407,000	1,811,000	2,989,000
Gross profit	1,294,000	799,000	3,388,000	4,803,000
Operating expenses
Research and development	972,000	1,097,000	2,918,000	3,231,000
Selling, general and administrative	955,000	1,059,000	3,054,000	2,963,000
Impairment of goodwill		420,000		420,000
Total operating expenses	1,927,000	2,576,000	5,972,000	6,614,000
Loss from operations	(633,000)	(1,777,000)	(2,584,000)	(1,811,000)
Interest expense	(70,000)	(54,000)	(181,000)	(164,000)
Other income (expense), net	(4,000)	30,000	14,000	81,000
Net loss	(707,000)	(1,801,000)	(2,751,000)	(1,894,000)
Deemed dividend for warrant exercise price adjustment			(392,000)
Net loss attributable to common stockholders	$ (707,000)	$ (1,801,000)	$ (3,143,000)	$ (1,894,000)
Net loss per share attributable to common stockholders
Basic and diluted	$ (0.20)	$ (0.83)	$ (1.03)	$ (0.88)
Shares used in computing net loss per share
Basic and diluted	3,546	2,171	3,037	2,161
Other comprehensive income, net of tax:
Net loss	$ (707,000)	$ (1,801,000)	$ (2,751,000)	$ (1,894,000)
Net unrealized gains on available-for-sale securities				1,000
Comprehensive loss	(707,000)	(1,801,000)	(2,751,000)	(1,893,000)
Product
Net revenue
Total net revenue	1,803,000	1,037,000	4,550,000	7,233,000
Royalty and Other
Net revenue
Total net revenue	$ 168,000	$ 169,000	$ 649,000	$ 559,000

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning Balance at Dec. 31, 2018	$ 7,157,000	$ 2,000	$ 243,022,000		$ (235,867,000)
Beginning Balance, shares at Dec. 31, 2018		2,148
Issuance of common stock for release of awards	(1,000)		(1,000)
Issuance of common stock for release of awards, shares		9
Stock-based compensation	(4,000)		(4,000)
Net income (loss)	10,000				10,000
Ending Balance at Mar. 31, 2019	7,162,000	$ 2,000	243,017,000		(235,857,000)
Ending Balance, shares at Mar. 31, 2019		2,157
Beginning Balance at Dec. 31, 2018	7,157,000	$ 2,000	243,022,000		(235,867,000)
Beginning Balance, shares at Dec. 31, 2018		2,148
Unrealized gain on available-for-sale investments	1,000
Net income (loss)	(1,894,000)
Ending Balance at Sep. 30, 2019	5,459,000	$ 2,000	243,217,000	$ 1,000	(237,761,000)
Ending Balance, shares at Sep. 30, 2019		2,178
Beginning Balance at Mar. 31, 2019	7,162,000	$ 2,000	243,017,000		(235,857,000)
Beginning Balance, shares at Mar. 31, 2019		2,157
Issuance of common stock for release of awards, shares		5
Stock-based compensation	119,000		119,000
Unrealized gain on available-for-sale investments	1,000			1,000
Net income (loss)	(103,000)				(103,000)
Ending Balance at Jun. 30, 2019	7,179,000	$ 2,000	243,136,000	1,000	(235,960,000)
Ending Balance, shares at Jun. 30, 2019		2,162
Issuance of common stock for release of awards	(3,000)		(3,000)
Issuance of common stock for release of awards, shares		16
Stock-based compensation	84,000		84,000
Net income (loss)	(1,801,000)				(1,801,000)
Ending Balance at Sep. 30, 2019	5,459,000	$ 2,000	243,217,000	$ 1,000	(237,761,000)
Ending Balance, shares at Sep. 30, 2019		2,178
Beginning Balance at Dec. 31, 2019	$ 4,836,000	$ 2,000	243,281,000		(238,447,000)
Beginning Balance, shares at Dec. 31, 2019	2,179	2,179
Issuance of common stock for release of awards	$ (1,000)		(1,000)
Issuance of common stock for release of awards, shares		20
Exercise of pre-funded warrants	2,000		2,000
Exercise of pre-funded warrants, shares		116
Stock-based compensation	68,000		68,000
Net income (loss)	(1,405,000)				(1,405,000)
Ending Balance at Mar. 31, 2020	3,500,000	$ 2,000	243,350,000		(239,852,000)
Ending Balance, shares at Mar. 31, 2020		2,315
Beginning Balance at Dec. 31, 2019	$ 4,836,000	$ 2,000	243,281,000		(238,447,000)
Beginning Balance, shares at Dec. 31, 2019	2,179	2,179
Deemed dividend for warrant exercise price adjustment	$ 392,000
Net income (loss)	(2,751,000)
Ending Balance at Sep. 30, 2020	$ 3,901,000	$ 3,000	245,488,000		(241,590,000)
Ending Balance, shares at Sep. 30, 2020	3,553	3,553
Beginning Balance at Mar. 31, 2020	$ 3,500,000	$ 2,000	243,350,000		(239,852,000)
Beginning Balance, shares at Mar. 31, 2020		2,315
Issuance of common stock for release of awards, shares		1
Sale of common stock, net of financing costs	1,619,000	$ 1,000	1,618,000
Sale of common stock, net of financing costs, shares		1,218
Deemed dividend for warrant exercise price adjustment	392,000		392,000		(392,000)
Stock-based compensation	66,000		66,000
Net income (loss)	(639,000)				(639,000)
Ending Balance at Jun. 30, 2020	4,546,000	$ 3,000	245,426,000		(240,883,000)
Ending Balance, shares at Jun. 30, 2020		3,534
Issuance of common stock for release of awards	(1,000)		(1,000)
Issuance of common stock for release of awards, shares		19
Stock-based compensation	63,000		63,000
Net income (loss)	(707,000)				(707,000)
Ending Balance at Sep. 30, 2020	$ 3,901,000	$ 3,000	$ 245,488,000		$ (241,590,000)
Ending Balance, shares at Sep. 30, 2020	3,553	3,553

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (2,751)	$ (1,894)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	121	148
Stock-based compensation	197	199
Impairment of goodwill		420
Accrued interest	181	164
Other	(5)	(11)
Changes in assets and liabilities:
Accounts receivable	385	729
Inventories	255	(67)
Prepaid expenses and other assets	174	448
Accounts payable	(138)	(105)
Deferred revenue and other liabilities	(35)	(257)
Net cash used in operating activities	(1,616)	(226)
Cash flows from investing activities:
Purchases of property and equipment	(14)	(62)
Proceeds from maturities of short-term investments	300	925
Purchases of short-term investments		(1,567)
Net cash provided by (used in) investing activities	286	(704)
Cash flows from financing activities:
Proceeds from sale of common stock, net of financing costs	1,619
Net proceeds from exercise of pre-funded warrants	2
Taxes paid to net share settle equity awards	(2)	(4)
Net cash provided by (used in) financing activities	2,198	(4)
Net increase (decrease) in cash and cash equivalents	868	(934)
Cash and cash equivalents at beginning of period	6,053	7,104
Cash and cash equivalents at end of period	6,921	6,170
Supplemental disclosure:
Issuance of convertible notes in settlement of accrued interest	234	$ 187
Fair value of warrant exercise price adjustment considered as deemed dividend	392
PPP Note
Cash flows from financing activities:
Proceeds from PPP note	$ 579

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
The Company and Summary of Significant Accounting Policies	Note 1. The Company and Summary of Significant Accounting Policies MoSys, Inc. (the Company) was incorporated in California in September 1991 and reincorporated in September 2000 in Delaware. The Company’s strategy and primary business objective is to be an IP-rich fabless semiconductor company focused on the development and sale of integrated circuit (IC) and related software and firmware products. The accompanying condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or for any other future period. Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year. Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates. Cash Equivalents and Investments The Company invests its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method. Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale securities, which consist primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities. Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. There was no allowance for doubtful accounts receivable at either September 30, 2020 or December 31, 2019. Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. The Company recorded a $0.1 million write down of inventory during the nine months ended September 30, 2020 and recorded no material inventory write-downs during the nine months ended September 30, 2019. Revenue Recognition The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer products. Accordingly, the recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company its and generally under agreements with payment terms typically less than 60 days. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. During the nine months ended September 30, 2020, the Company recognized revenue of $0.2 million that had been included in deferred revenue as of December 31, 2019. See Note 5 for disaggregation of revenue by geography. Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products. Warrants As of September 30, 2020, the Company had the following warrants outstanding (share amounts in thousands): Warrant type Number of Shares Exercise Price Expiration Common stock 33 $ 47.00 January 2023 Common stock 1,846 $ 2.40 October 2023 Per Share Amounts Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share gives effect to all potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with the outstanding convertible notes. The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): September 30, 2020 2019 Options outstanding to purchase common stock 160 82 Unvested restricted common stock units 60 91 Convertible notes 271 245 Warrants 1,879 1,994 Total 2,370 2,412

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 2: Fair Value of Financial Instruments The estimated fair values of financial instruments outstanding were (in thousands): September 30, 2020 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 6,921 $ — $ — $ 6,921 December 31, 2019 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 6,053 $ — $ — $ 6,053 Short-term investments 300 — — 300 $ 6,353 $ — $ — $ 6,353 The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): September 30, 2020 Fair Value Level 1 Level 2 Level 3 Money market funds $ 3,893 $ 3,893 $ — $ — December 31, 2019 Fair Value Level 1 Level 2 Level 3 Money market funds $ 4,574 $ 4,574 $ — $ — Corporate notes and commercial paper $ 300 $ — $ 300 $ — There were no transfers in or out of Level 1 and Level 2 securities during the nine months ended September 30, 2020 or 2019.

Balance Sheet Detail

Balance Sheet Detail	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Detail	Note 3. Balance Sheet Detail September 30, December 31, 2020 2019 (in thousands) Inventories: Work-in-process $ 514 $ 746 Finished goods 199 222 $ 713 $ 968

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 4. Commitments and Contingencies Indemnification In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the nine months ended September 30, 2020 or 2019 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any material payments related to these indemnification agreements. Legal Matters The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.

Business Segments, Concentratio

Business Segments, Concentration of Credit Risk and Significant Customers	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Business Segments, Concentration of Credit Risk and Significant Customers	Note 5. Business Segments, Concentration of Credit Risk and Significant Customers The Company operates in one business segment and uses one measurement of profitability for its business. Net revenue is attributed to the United States and to all foreign countries based on the geographical location of the customer. The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 North America $ 1,494 $ 930 $ 4,112 $ 6,004 Japan 343 179 593 1,431 Taiwan 93 97 340 225 Rest of world 41 — 154 132 Total net revenue $ 1,971 $ 1,206 $ 5,199 $ 7,792 Customers who accounted for at least 10% of total net revenue were: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Customer A 33% *% 32% *% Customer B 24% 15% 26% 13% Customer C 17% 15% 11% *% Customer D 11% 33% *% 27% * Represents less than 10% Four customers accounted for 79% of accounts receivable as of September 30, 2020. Four customers accounted for 85% of accounts receivable as of December 31, 2019.

Income Tax Provision

Income Tax Provision	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax Provision	Note 6. Income Tax Provision The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2014 to 2019 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years 2010 to 2019. As of September 30, 2020, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions. The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted on March 27, 2020 in the United States. The CARES Act includes several significant provisions for corporations, including the usage of net operating losses and payroll benefits. As a result of the CARES Act, the Company was able to file for and collect a $0.1 million federal tax receivable for a prior-period alternative minimum tax credit.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Note 7. Stock-Based Compensation The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The unamortized compensation cost, as of September 30, 2020, was $0.2 million related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 1.7 years. The expense related to restricted stock units (RSUs) is generally recognized over a three vesting period and is based on the fair value of the underlying stock on the dates of grant. The unamortized compensation cost, as of September 30, 2020, was $0.3 million related to RSUs and is expected to be recognized as expense over a weighted-average period of approximately 0.8 years. For the nine months ended September 30, 2020 and 2019, there were no excess tax benefits associated with the exercise of stock options due to the Company’s historical loss positions. Valuation Assumptions There were no stock options granted during the nine months ended September 30, 2020. The fair value of the Company’s stock options granted during the nine months ended September 30, 2019 was estimated on the grant dates using the Black-Scholes valuation option-pricing model with the following assumptions: Nine Months Ended September 30, 2019 Risk-free interest rate 2.5 % Volatility 128.4 % Expected life (years) 3.0 - 5.0 Dividend yield — % The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. The expected volatility was based on the historical volatility of the Company’s stock price over the expected term of the options. The expected term of options granted was derived from historical data based on employee exercises and post‑vesting employment termination behavior. A dividend yield of zero is applied because the Company has never paid dividends and has no intention to pay dividends in the near future. The Company accounts for forfeitures as they occur. Common Stock Options and Restricted Stock In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and, as a result, the Amended and Restated 2010 Equity Incentive Plan (the 2010 Plan) was terminated. No future grants of awards will be made under the 2010 Plan, although it will continue to govern prior awards granted thereunder, until all such awards granted have been exercised, forfeited, canceled, expired or otherwise terminated in accordance with their terms. The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares have been reserved for issuance. The term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, options granted under the 2019 Plan will vest over a three to four-year period and have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company. The following table summarizes the activity in the shares available for grant under the 2019 Plan during the nine months ended September 30, 2020 (in thousands, except exercise price): Options outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance as of January 1, 2020 88 161 $ 10.85 RSUs granted (3 ) — — Options cancelled — (1 ) $ 4.00 Balance as of September 30, 2020 85 160 $ 10.90 A summary of RSU activity under the 2019 Plan and the 2010 Plan is presented below (in thousands, except for fair value): Weighted Average Number of Grant-Date Shares Fair Value Non-vested shares as of January 1, 2020 103 $ 3.75 Vested (21 ) $ 3.80 Non-vested shares as of March 31, 2020 82 $ 3.74 Cancelled (1 ) $ 4.55 Non-vested shares as of June 30, 2020 81 $ 3.73 Granted 3 $ 1.87 Vested (20 ) $ 3.56 Cancelled (4 ) $ 4.00 Non-vested shares as of September 30, 2020 60 $ 3.58 The total intrinsic value of the RSUs outstanding as of September 30, 2020 was $0.1 million. The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2020 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $1.57 - $14.99 143 8.51 $ 2.63 54 $ 2.99 $ — $15.00 - $25.59 8 2.99 $ 15.00 8 $ 15.00 $ — $25.60 - $143.99 3 3.61 $ 41.88 3 $ 41.83 $ — $144.00 - $409.99 5 5.90 $ 144.00 5 $ 144.00 $ — $410.00 - $924.00 1 4.44 $ 430.64 1 $ 430.64 $ — $1.57 - $924.00 160 8.04 $ 11.02 71 $ 21.59 $ — There were no stock options exercised during the nine months ended September 30, 2020 or 2019.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders Equity Note [Abstract]
Stockholders' Equity	Note 8: Stockholders’ Equity On April 21, 2020, the Company completed a registered direct offering of securities under an effective registration statement filed with the SEC pursuant to the Securities Act of 1933, as amended. In the offering, the Company sold 1,218,000 shares of common stock at a price of $1.56 per share to institutional investors. Net proceeds of the offering, after placement agent and other fees and expenses paid by the Company, were approximately $1.6 million. As a result of the offering, the exercise price of the 1,845,540 outstanding common stock purchase warrants that were issued in October 2018 was reduced from $6.00 per share to $2.40 per share. During the quarter ended June 30, 2020, the Company accounted for the warrant exercise price adjustment in accordance with Accounting Standards Codification Topic 260 and determined that the change in the exercise price resulted in a deemed dividend of $392,000 that increased the net loss attributable to common stockholders.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Notes Payable	Note 9. Notes Payable Convertible Notes In March 2016, the Company entered into a 10% Senior Secured Convertible Note Purchase Agreement (the Purchase Agreement) with the purchasers of $8,000,000 principal amount of 10% Senior Secured Convertible Notes due August 15, 2018 (the Notes), at par, in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Pursuant to amendments to the Notes and related documents in February and October 2018, the interest rate was reduced to 8%, the maturity date of the Notes was extended to August 15, 2023, and the optional conversion price was reduced from $170.00 of Note principal per share of common stock to $11.434 of Note principal per share of common stock. The conversion price is subject to adjustment upon certain events, such as stock splits, reverse stock splits, stock dividends and similar kinds of transactions, as set forth in the Purchase Agreement. Pursuant to a security agreement, the Notes are secured by a security interest in all of the assets of the Company. Accrued interest is payable semi-annually in cash or in kind through the issuance of identical new Notes, or with a combination of the two, at the Company’s option. The Notes are noncallable and nonredeemable by the Company. The Notes are redeemable at the election of the holders if the Company experiences a fundamental change (as defined in the Notes), which generally would occur in the event (i) any person acquires beneficial ownership of shares of common stock of the Company entitling such person to exercise at least 40% of the total voting power of all of the shares of capital stock of the Company entitled to vote generally in elections of directors, (ii) an acquisition of the Company by another person through a merger or consolidation, or the sale, transfer or lease of all or substantially all of the Company’s assets, or (iii) the Company’s current directors cease to constitute a majority of the board of directors of the Company within a 12-month period, disregarding for this purpose any director who voluntarily resigns as a director or dies while serving as a director. Effective February 2018, pursuant to one amendment to the Notes, the redemption price was reduced from 120% to 100% of the principal amount of the Note to be repurchased plus accrued and unpaid interest as of the redemption date. No Note holder shall be entitled to convert such holder’s Note if effective upon the applicable conversion date (i) the holder would have beneficial ownership of more than 19.9% of the voting capital stock of the Company as determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, (with exceptions specified in the Purchase Agreement), or (ii) if the shares are being acquired or held with a purpose or effect of changing or influencing control of the Company, or in connection with or as a participant in any transaction having that purpose or effect, as determined in the sole discretion of the board of directors of the Company. There is no required sinking fund for the Notes. The Notes have not been registered for resale, and the holder(s) do not have registration rights. The Notes restrict the ability of the Company to incur any indebtedness for borrowed money, unless such indebtedness by its terms is expressly subordinated to the Notes in right of payment and to the security interest of the Note holder(s) in respect to the priority and enforcement of any security interest in property of the Company securing such new debt; provided that the Note holder(s) security interest and cash payment rights under the Notes shall be subordinate to a maximum of $5,000,000 of indebtedness for a secured accounts receivable line of credit facility provided to the Company by a bank or institutional lender; and, provided further, that in no event may the amount of indebtedness to which the security interest of the Note holder(s) is subordinated exceed the outstanding balance of accounts receivable less than 90 days old for which the Company has not recorded an allowance for doubtful accounts pledged under such credit facility. The Notes define an event of default generally as any failure by the Company to pay an amount owed under the Notes when due (subject to cure periods), a default with respect to other indebtedness of the Company resulting in acceleration of such indebtedness, the commencement of bankruptcy or insolvency proceedings, or the cessation of business. If an event of default occurs under the Notes, the holder(s) of a majority-in-interest of the outstanding principal amount of the Notes may declare the outstanding principal amount thereof to be immediately due and payable and pursue all available remedies, including taking possession of the assets of the Company and selling them to pay the amount of debt then due, plus expenses, in accordance with applicable laws and procedures. In accordance with the October 2018 amendment to the Notes, the Company used $7.4 million of the proceeds from a public offering of securities effected in October 2018 to repay a portion of the Notes. Semi-annual interest payments have been made in each of February 2019, August 2019, February 2020 and August 2020 for approximately $78,000, $109,000, $112,000 and $122,000, respectively, in-kind with the issue of additional notes (Interest Notes) to the Purchasers. The Interest Notes have terms identical to the Notes. At September 30, 2020, the Notes, Interest Notes and accrued interest could be converted into a maximum of 271,121 shares of common stock at $11.434 per share, excluding the effects of future payments of interest in-kind and a beneficial ownership ceiling of 9.9%. The $3.1 million of outstanding Notes are payable in full in 2023. PPP Note On May 7, 2020, the Company entered into a Promissory Note with Wells Fargo Bank, N.A. (the Lender) in an aggregate principal amount of $579,330 (the PPP Note), pursuant to the Paycheck Protection Program (the PPP) under the CARES Act. The term of the PPP Note is two years. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate of 1.0%, which shall be deferred for the first ten months of the term of the PPP Note. Monthly payments will be due and payable beginning in March 2021 and continue each month thereafter until maturity of the PPP Note. The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or filing suit and obtaining judgment against the Company. The Company may apply to the Lender for forgiveness of the PPP Note, under the terms of the PPP. No assurance is provided that the Company will obtain forgiveness of the PPP Note in whole or in part, but the Company believes it has used the proceeds in accordance with the PPP. If the PPP Note is not forgiven, principal payments will be due: $244,000 in 2021, $292,000 in 2022, and $43,330 in 2023.

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	Note 10. Leases Effective January 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2016-02, as amended, using the alternative transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the “effective date method”). Under the effective date method, comparative periods are presented under previous GAAP, Accounting Standards Codification 840, and do not include any retrospective adjustments to reflect the adoption of ASU No. 2016-02. As an accounting policy, the Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components. The Company also has elected the package of transition provisions available for existing contracts, which allowed the Company to carryforward its historical assessments of (i) whether contracts are or contain leases, (ii) lease classification and (iii) initial direct costs. The adoption did not result in a cumulative-effect adjustment to the opening balance of accumulated deficit. As a result of the adoption, the Company recorded an operating lease right-of-use asset of $0.4 million and corresponding short-term and long-term liabilities of $0.2 million and $0.2 million, respectively, as of January 1, 2019. The adoption of ASU No. 2016-02 did not have a material impact on the Company’s condensed consolidated statement of operations and comprehensive income or cash flows as of the adoption date. The Company identified only one lease to be accounted for under ASU No. 2016-02, which was the lease for its corporate facility that had an initial expiration date of October 31, 2020. The right-of-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. The discount rate used to measure the lease asset and liability represents the interest rate on the Notes (8%). Lease expense is recognized on a straight-line basis over the lease term, and operating lease expense was $0.2 million for the nine months ended September 30, 2020. On September 30, 2020, the Company and the lessor extended the lease for an additional 20.5 month term commencing November 1, 2020. The Company does not have an option to extend the lease term beyond the current extension. The extension was accounted for as a lease modification at September 30, 2020. The Company assessed the lease classification of the facility lease at the modification date and determined that the facility lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been remeasured based on the present value of remaining lease payments over the remaining extended lease term. Non-lease components are not included in the right-of-use asset and liability and are reflected as expense in the period incurred. Future minimum payments under the facility operating lease at September 30, 2020 are as follows (in thousands): Operating Year ending December 31, lease 2020 $ 52 2021 206 2022 112 Total future lease payments 370 Less: imputed interest (17 ) Present value of lease liabilities $ 353 Supplemental cash flow information related to the operating lease was as follows (in thousands): Nine Months Ended September 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 168 $ 163 Non-cash activity: Recognition of additional right-of-use asset and liability upon lease modification $ 352 $ —

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.
Cash Equivalents and Investments	Cash Equivalents and Investments The Company invests its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method.
Fair Value Measurements	Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale securities, which consist primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities. Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. There was no allowance for doubtful accounts receivable at either September 30, 2020 or December 31, 2019.
Inventories	Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. The Company recorded a $0.1 million write down of inventory during the nine months ended September 30, 2020 and recorded no material inventory write-downs during the nine months ended September 30, 2019.
Revenue Recognition	Revenue Recognition The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer products. Accordingly, the recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company its and generally under agreements with payment terms typically less than 60 days. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. During the nine months ended September 30, 2020, the Company recognized revenue of $0.2 million that had been included in deferred revenue as of December 31, 2019. See Note 5 for disaggregation of revenue by geography.
Cost of Net Revenue	Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products.
Warrants	Warrants As of September 30, 2020, the Company had the following warrants outstanding (share amounts in thousands): Warrant type Number of Shares Exercise Price Expiration Common stock 33 $ 47.00 January 2023 Common stock 1,846 $ 2.40 October 2023
Per Share Amounts	Per Share Amounts Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share gives effect to all potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with the outstanding convertible notes. The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): September 30, 2020 2019 Options outstanding to purchase common stock 160 82 Unvested restricted common stock units 60 91 Convertible notes 271 245 Warrants 1,879 1,994 Total 2,370 2,412

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Outstanding Warrants	As of September 30, 2020, the Company had the following warrants outstanding (share amounts in thousands): Warrant type Number of Shares Exercise Price Expiration Common stock 33 $ 47.00 January 2023 Common stock 1,846 $ 2.40 October 2023
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): September 30, 2020 2019 Options outstanding to purchase common stock 160 82 Unvested restricted common stock units 60 91 Convertible notes 271 245 Warrants 1,879 1,994 Total 2,370 2,412

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Estimated Fair Values of Financial Instruments Outstanding	The estimated fair values of financial instruments outstanding were (in thousands): September 30, 2020 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 6,921 $ — $ — $ 6,921 December 31, 2019 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 6,053 $ — $ — $ 6,053 Short-term investments 300 — — 300 $ 6,353 $ — $ — $ 6,353
Schedule of Fair Value Hierarchy for Financial Assets (Cash Equivalents and Investments)	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): September 30, 2020 Fair Value Level 1 Level 2 Level 3 Money market funds $ 3,893 $ 3,893 $ — $ — December 31, 2019 Fair Value Level 1 Level 2 Level 3 Money market funds $ 4,574 $ 4,574 $ — $ — Corporate notes and commercial paper $ 300 $ — $ 300 $ —

Balance Sheet Detail (Tables)

Balance Sheet Detail (Tables)	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Inventory	September 30, December 31, 2020 2019 (in thousands) Inventories: Work-in-process $ 514 $ 746 Finished goods 199 222 $ 713 $ 968

Business Segments, Concentrat_2

Business Segments, Concentration of Credit Risk and Significant Customers (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of Revenue from Shipment of Product and Licensing of its Technologies to Customers by Geographical Location	The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 North America $ 1,494 $ 930 $ 4,112 $ 6,004 Japan 343 179 593 1,431 Taiwan 93 97 340 225 Rest of world 41 — 154 132 Total net revenue $ 1,971 $ 1,206 $ 5,199 $ 7,792
Schedule of Customers Who Accounted for at Least 10% of Total Net Revenue	Customers who accounted for at least 10% of total net revenue were: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Customer A 33% *% 32% *% Customer B 24% 15% 26% 13% Customer C 17% 15% 11% *% Customer D 11% 33% *% 27% * Represents less than 10%

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Assumptions used in Estimation of Fair Value of the Share-based Payment Awards on the Grant Date	Nine Months Ended September 30, 2019 Risk-free interest rate 2.5 % Volatility 128.4 % Expected life (years) 3.0 - 5.0 Dividend yield — %
Summary of Share Available for Grant Under the 2019 Plan	The following table summarizes the activity in the shares available for grant under the 2019 Plan during the nine months ended September 30, 2020 (in thousands, except exercise price): Options outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance as of January 1, 2020 88 161 $ 10.85 RSUs granted (3 ) — — Options cancelled — (1 ) $ 4.00 Balance as of September 30, 2020 85 160 $ 10.90
Summary of RSU Activity under the 2019 and 2010 Plan	A summary of RSU activity under the 2019 Plan and the 2010 Plan is presented below (in thousands, except for fair value): Weighted Average Number of Grant-Date Shares Fair Value Non-vested shares as of January 1, 2020 103 $ 3.75 Vested (21 ) $ 3.80 Non-vested shares as of March 31, 2020 82 $ 3.74 Cancelled (1 ) $ 4.55 Non-vested shares as of June 30, 2020 81 $ 3.73 Granted 3 $ 1.87 Vested (20 ) $ 3.56 Cancelled (4 ) $ 4.00 Non-vested shares as of September 30, 2020 60 $ 3.58
Summary of Significant Ranges of Outstanding and Exercisable Options	The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2020 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $1.57 - $14.99 143 8.51 $ 2.63 54 $ 2.99 $ — $15.00 - $25.59 8 2.99 $ 15.00 8 $ 15.00 $ — $25.60 - $143.99 3 3.61 $ 41.88 3 $ 41.83 $ — $144.00 - $409.99 5 5.90 $ 144.00 5 $ 144.00 $ — $410.00 - $924.00 1 4.44 $ 430.64 1 $ 430.64 $ — $1.57 - $924.00 160 8.04 $ 11.02 71 $ 21.59 $ —

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Schedule of Future Minimum Payments under Facility Operating Lease	Future minimum payments under the facility operating lease at September 30, 2020 are as follows (in thousands): Operating Year ending December 31, lease 2020 $ 52 2021 206 2022 112 Total future lease payments 370 Less: imputed interest (17 ) Present value of lease liabilities $ 353
Schedule of Supplemental Cash Flow Information Related to Operating lease	Supplemental cash flow information related to the operating lease was as follows (in thousands): Nine Months Ended September 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 168 $ 163 Non-cash activity: Recognition of additional right-of-use asset and liability upon lease modification $ 352 $ —

The Company and Summary of Si_4

The Company and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Accounting Policies [Abstract]
Maximum specific allowance as percentage of invoice value for problematic customer balances	100.00%
Allowance for doubtful accounts receivable	$ 0		$ 0
Inventory write-downs	$ 100,000	$ 0
Payment terms	The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically less than 60 days.
Deferred revenue, revenue recognized	$ 200,000

The Company and Summary of Si_5

The Company and Summary of Significant Accounting Policies - Summary of Outstanding Warrants (Details) - $ / shares	Sep. 30, 2020	Apr. 21, 2020	Oct. 31, 2018
Class Of Warrant Or Right [Line Items]
Exercise Price		$ 2.40	$ 6
Common Stock Warrants One
Class Of Warrant Or Right [Line Items]
Number of Shares	33
Exercise Price	$ 47
Expiration	Jan. 30, 2023
Common Stock Warrants Two
Class Of Warrant Or Right [Line Items]
Number of Shares	1,846
Exercise Price	$ 2.40
Expiration	Oct. 30, 2023

The Company and Summary of Si_6

The Company and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,370	2,412
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	160	82
RSU's
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	60	91
Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	271	245
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,879	1,994

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Estimated Fair Values of Financial Instruments Outstanding (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Cost		$ 6,353
Unrealized Gains		0
Unrealized Losses		0
Fair Value		6,353
Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Cost	$ 6,921	6,053
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	$ 6,921	6,053
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Cost		300
Unrealized Gains		0
Unrealized Losses		0
Fair Value		$ 300

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy for Financial Assets (Cash Equivalents and Investments) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 3,893	$ 4,574
Money market funds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 3,893	4,574
Corporate notes and commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value		300
Corporate notes and commercial paper | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value		$ 300

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Transfer of assets between Level 1 to Level 2	$ 0	$ 0
Transfer of assets between Level 2 to Level 1	0	0
Transfer of liabilities between Level 1 to Level 2	0	0
Transfer of liabilities between Level 2 to Level 1	$ 0	$ 0

Balance Sheet Detail - Schedule

Balance Sheet Detail - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Work-in-process	$ 514	$ 746
Finished goods	199	222
Total	$ 713	$ 968

Business Segments, Concentrat_3

Business Segments, Concentration of Credit Risk and Significant Customers - Additional Information (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2020SegmentCustomer	Dec. 31, 2019Customer
Business Segments
Number of business segments | Segment	1
Number of measurements of profitability	1
Accounts receivable | Major customers | Credit concentration
Business Segments
Percentage of concentration risk	79.00%	85.00%
Number of customers | Customer	4	4

Business Segments, Concentrat_4

Business Segments, Concentration of Credit Risk and Significant Customers - Schedule of Revenue from Shipment of Product and Licensing of its Technologies to Customers by Geographical Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Business Segments
Total net revenue	$ 1,971	$ 1,206	$ 5,199	$ 7,792
North America [Member]
Business Segments
Total net revenue	1,494	930	4,112	6,004
Japan [Member]
Business Segments
Total net revenue	343	179	593	1,431
Taiwan [Member]
Business Segments
Total net revenue	93	$ 97	340	225
Rest of world [Member]
Business Segments
Total net revenue	$ 41		$ 154	$ 132

Business Segments, Concentrat_5

Business Segments, Concentration of Credit Risk and Significant Customers - Schedule of Customers Who Accounted for at Least 10% of Total Net Revenue (Details) - Net Revenues - Customer Concentration	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Customer A
Significant Customers
Percentage of concentration risk	33.00%		32.00%
Customer B
Significant Customers
Percentage of concentration risk	24.00%	15.00%	26.00%	13.00%
Customer C
Significant Customers
Percentage of concentration risk	17.00%	15.00%	11.00%
Customer D
Significant Customers
Percentage of concentration risk	11.00%	33.00%		27.00%

Income Tax Provision - Addition

Income Tax Provision - Additional Information (Details)	Sep. 30, 2020USD ($)
Income Taxes [Line Items]
Unrecognized tax benefits recorded as liability	$ 0
CARES Act
Income Taxes [Line Items]
Federal tax receivable for prior period alternative minimum tax credit	$ 100,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted (in shares)	0
Stock Incentive Plan 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance	182,500
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unamortized compensation cost, net of expected forfeitures	$ 200,000
Weighted average expected period over which the expense is to be recognized	1 year 8 months 12 days
Tax benefits associated with exercise of stock options	$ 0	$ 0
Dividend yield (as a percent)	0.00%	0.00%
Stock options exercised	0	0
Options | Stock Incentive Plan 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum percentage of voting rights required for applicability of a specific expiration term	10.00%
Maximum expiration term of options granted	5 years
Term of plan	10 years
Options | Stock Incentive Plan 2019 | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of replacement options	3 years
Options | Stock Incentive Plan 2019 | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of replacement options	4 years
Options | Equity Incentive Plan 2010
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted (in shares)	0
RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average expected period over which the expense is to be recognized	9 months 18 days
Stock-based compensation expense, recognition period	3 years
Unamortized compensation cost, net of expected forfeitures	$ 300,000
RSU's | Equity Incentive Plan 2010
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of the restricted stock units outstanding	$ 100,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of the Share-based Payment Awards on the Grant Date (Details) - Options	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate		2.50%
Volatility		128.40%
Dividend yield	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)		3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)		5 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Share Available for Grant Under the 2019 Plan (Details) - Equity Incentive Plan 2019 [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Shares Available for Grant
Balance at the beginning of the year (in shares)	88
Balance at the end of the period (in shares)	85
Number of Shares
Balance at the beginning of the year (in shares)	161
Options cancelled	(1)
Balance at the end of the period (in shares)	160
Weighted Average Exercise Prices
Weighted-average exercise price (in dollars per share) | $ / shares	$ 10.85
Options cancelled | $ / shares	4
Weighted-average exercise price (in dollars per share) | $ / shares	$ 10.90
RSU
Shares Available for Grant
Granted	(3)

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity under the 2019 and 2010 Plan (Details) - Equity Incentive Plan 2010 - RSU's - $ / shares	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2020
Number of Shares
Non-vested shares at the beginning of the year	81,000	82,000	103,000	103,000
Granted (in shares)	3,000
Vested (in shares)	(20,000)		(21,000)
Cancelled (in shares)	(4,000)	(1,000)
Non-vested shares at the end of the period	60,000	81,000	82,000	60,000
Weighted Average Grant-Date Fair Value
Weighted average grant date fair value	$ 3.73	$ 3.74	$ 3.75	$ 3.75
RSUs granted	1.87
Vested (in dollars per share)	3.56		3.80
Cancelled (in dollars per shares)	4	4.55
Weighted average grant date fair value	$ 3.58	$ 3.73	$ 3.74	$ 3.58

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Significant Ranges of Outstanding and Exercisable Options (Details) - Options shares in Thousands	9 Months Ended
	Sep. 30, 2020$ / sharesshares
$1.57 - $14.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 1.57
Upper range limit (in dollars per share)	$ 14.99
Number Outstanding (in shares) | shares	143
Weighted Average Remaining Contractual Life	8 years 6 months 3 days
Weighted Average Exercise Price (in dollars per share)	$ 2.63
Number Exercisable (in shares) | shares | shares	54
Weighted Average Exercise Price (in dollars per share)	$ 2.99
$15.00 - $25.59
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	15
Upper range limit (in dollars per share)	$ 25.59
Number Outstanding (in shares) | shares	8
Weighted Average Remaining Contractual Life	2 years 11 months 26 days
Weighted Average Exercise Price (in dollars per share)	$ 15
Number Exercisable (in shares) | shares | shares	8
Weighted Average Exercise Price (in dollars per share)	$ 15
$25.60 - $143.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	25.60
Upper range limit (in dollars per share)	$ 143.99
Number Outstanding (in shares) | shares	3
Weighted Average Remaining Contractual Life	3 years 7 months 9 days
Weighted Average Exercise Price (in dollars per share)	$ 41.88
Number Exercisable (in shares) | shares | shares	3
Weighted Average Exercise Price (in dollars per share)	$ 41.83
$144.00 - $409.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	144
Upper range limit (in dollars per share)	$ 409.99
Number Outstanding (in shares) | shares	5
Weighted Average Remaining Contractual Life	5 years 10 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 144
Number Exercisable (in shares) | shares | shares	5
Weighted Average Exercise Price (in dollars per share)	$ 144
$410.00 - $924.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	410
Upper range limit (in dollars per share)	$ 924
Number Outstanding (in shares) | shares	1
Weighted Average Remaining Contractual Life	4 years 5 months 8 days
Weighted Average Exercise Price (in dollars per share)	$ 430.64
Number Exercisable (in shares) | shares | shares	1
Weighted Average Exercise Price (in dollars per share)	$ 430.64
$1.57 - $924.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	1.57
Upper range limit (in dollars per share)	$ 924
Number Outstanding (in shares) | shares	160
Weighted Average Remaining Contractual Life	8 years 14 days
Weighted Average Exercise Price (in dollars per share)	$ 11.02
Number Exercisable (in shares) | shares | shares	71
Weighted Average Exercise Price (in dollars per share)	$ 21.59

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	Apr. 21, 2020	Oct. 31, 2018	Jun. 30, 2020	Sep. 30, 2020
Stockholders Equity Note [Abstract]
Number of common stock sold	1,218,000
Sale of stock, price per share	$ 1.56
Net proceeds of the offering	$ 1,600,000
Units offered during the period		1,845,540
Exercise price of warrants	$ 2.40	$ 6
Deemed dividend for warrant exercise price adjustment			$ 392,000	$ 392,000

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) - USD ($)	May 07, 2020	Feb. 18, 2018	Feb. 17, 2018	Aug. 31, 2020	Feb. 29, 2020	Aug. 31, 2019	Feb. 28, 2019	Oct. 31, 2018	Mar. 31, 2016	Sep. 30, 2020
Debt Instrument [Line Items]
Stated interest rate										8.00%
Senior Secured Convertible Notes due August 15 2018
Debt Instrument [Line Items]
Stated interest rate								8.00%	10.00%
Principal amount									$ 8,000,000
Redemption purchase price		100.00%	120.00%
Minimum ownership percentage triggering event for redemption of notes									40.00%
Maximum amount of indebtedness subordinated by security interest and cash payment rights under debt instruments									$ 5,000,000
Payment on principle amount of note								$ 7,400,000
Senior Secured Convertible Notes due August 15 2018 | Maximum
Debt Instrument [Line Items]
Period for outstanding balance of accounts receivable has not recorded an allowance for doubtful accounts									90 days
Senior Secured Convertible Notes due August 15 2018 | Minimum
Debt Instrument [Line Items]
Percentage of beneficial ownership if effective upon conversion date of debt instrument									19.90%
Senior Secured Convertible Notes due August 15, 2023
Debt Instrument [Line Items]
Conversion price								$ 11.434	$ 170
Outstanding Notes payable										$ 3,100,000
Interest Note and Accrued Interest
Debt Instrument [Line Items]
Conversion price										$ 11.434
Semi-annual interest payments				$ 122,000	$ 112,000	$ 109,000	$ 78,000
Number of shares issuable if notes converted to shares of common stock										271,121
Beneficial ownership ceiling										9.90%
Promissory Note | Paycheck Protection Program
Debt Instrument [Line Items]
Stated interest rate	1.00%
Principal amount	$ 579,330
Debt instrument term	2 years
Monthly payment beginning date	Mar. 31, 2021
Principal payments due in 2021	$ 244,000
Principal payments due in 2022	292,000
Principal payments due in 2023	$ 43,330

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Jan. 01, 2019
Leases [Abstract]
Right-of-use lease asset	$ 352	$ 156	$ 400
Short-term lease liability	201	$ 166	200
Long-term lease liability	$ 152		$ 200
Interest rate	8.00%
Operating leases expense	$ 200
Operating leases initial expiration period	2020-10
Option to extend additional lease term	20 months 15 days
Operating lease, option to extend	Lessor extended the lease for an additional 20.5 month term commencing November 1, 2020. The Company does not have an option to extend the lease term beyond the current extension.

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments under Facility Operating Lease (Details) $ in Thousands	Sep. 30, 2020USD ($)
Leases, Operating [Abstract]
2020	$ 52
2021	206
2022	112
Total future lease payments	370
Less: imputed interest	(17)
Present value of lease liabilities	$ 353

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Operating lease (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for lease	$ 168	$ 163
Non-cash activity:
Recognition of additional right-of-use asset and liability upon lease modification	$ 352